Cough is a protective reflex that clears the airways of secretions and foreign material, but when persistent or non-productive it becomes a distressing symptom requiring pharmacological intervention. Antitussives, expectorants, mucolytics, and demulcents represent the major drug classes used in cough management, each targeting different aspects of the cough reflex and mucus physiology.
What Are Antitussives and Mucolytics?
Antitussive agents suppress coughing by acting on the cough center centrally or peripherally. Expectorants aim to increase mucus production and hydration to facilitate clearance, while mucolytics break down the structural components of mucus to reduce viscosity. Demulcents coat the pharyngeal mucosa to soothe irritation.
Drug Classes and Mechanisms
Central antitussives include dextromethorphan, a non-opioid derivative of levorphanol that acts on sigma-1 receptors and NMDA receptors in the cough center. Codeine and pholcodine are opioid antitussives that suppress cough via mu-opioid receptors in the medulla. Codeine is a prodrug requiring CYP2D6 conversion to morphine, leading to variable efficacy based on genetic polymorphisms. Pholcodine has been withdrawn in several countries due to anaphylaxis risk with neuromuscular blocking agents.
Peripheral antitussives include levodropropizine and moguisteine, which modulate sensory nerve endings in the respiratory tract. These agents have a limited role in routine clinical practice.
Expectorants such as guaifenesin increase respiratory tract fluid secretion, reducing mucus viscosity and enhancing cough productivity. Hypertonic saline nebulization osmotically draws water into the airway lumen, improving mucociliary clearance.
Mucolytics chemically break down mucus glycoprotein structures. Acetylcysteine reduces disulfide bonds in mucus, decreasing viscosity. Carbocisteine and its derivative carbocisteine lysine modify mucus composition by reducing sialomucin production. Ambroxol and bromhexine stimulate surfactant production and increase serous airway secretion, improving mucus clearance.
Demulcents including honey, glycerin, and various syrups form a protective coating on the pharyngeal mucosa, reducing irritation and the cough reflex through a soothing mechanism.
Therapeutic Uses
Acute cough from upper respiratory tract infections is typically self-limiting and often does not require pharmacological treatment. Antitussives are indicated for dry, non-productive cough that interferes with sleep or daily activities. Chronic cough requires investigation of underlying causes such as asthma, GERD, or postnasal drip. Mucolytics are most useful in conditions with thick, tenacious secretions including COPD, cystic fibrosis, and bronchiectasis. Expectorants are widely available over the counter for productive coughs.
Adverse Effects
Dextromethorphan may cause drowsiness, dizziness, and at high doses dissociative effects and abuse potential. Opioid antitussives cause constipation, sedation, nausea, and carry dependence risk. Acetylcysteine may cause bronchospasm in asthmatic patients and gastrointestinal discomfort. Guaifenesin is generally well tolerated with mild nausea as the most common side effect.
Key Clinical Considerations
The evidence for over-the-counter cough medications is limited, particularly in children, where they are not recommended under six years of age. Cough suppressants should not be used in productive cough where mucus clearance is important. Acetylcysteine is also used as an antidote for acetaminophen overdose, an important secondary property. Most acute coughs resolve spontaneously, and patient education about expected duration is valuable.
Conclusion
Antitussives and mucolytics serve complementary roles in cough management, with selection based on cough character and underlying etiology. Judicious use, particularly avoidance of suppressants in productive cough, ensures appropriate symptom relief without interfering with protective airway clearance mechanisms.
